Monica Borgonovi

In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic

Gianpaolo Candiani, Monica Abbondi, Monica Borgonovi et al. · Journal of Antimicrobial Chemotherapy · 1999 · 150 citations

Activities of Ceftazidime and Avibactam against β-Lactamase-Producing Enterobacteriaceae in a Hollow-Fiber Pharmacodynamic Model

Ken Coleman, Premavathy Levasseur, Anne-Marie Girard et al. · Antimicrobial Agents and Chemotherapy · 2014 · 85 citations · Full text

Discovery of<i>N</i>-(3-Carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4<i>H</i>-thieno[2,3-<i>c</i>]pyran-2-yl)-l<i>H</i>-pyrazole-5-carboxamide (GLPG1837), a Novel Potentiator Which Can Open Class III Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channels to a High Extent

Steven E. Van der Plas, Hans Kelgtermans, Tom De Munck et al. · Journal of Medicinal Chemistry · 2017 · 58 citations · Full text

Teicoplanin metabolism in humans

A. Bernareggi, Angelo Borghi, Monica Borgonovi et al. · Antimicrobial Agents and Chemotherapy · 1992 · 54 citations · Full text

Medicinal Chemistry, Pharmaceutical Chemistry, Biochemistry +14

Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis

Oscar Mammoliti, Adeline Palisse, Caroline Joannesse et al. · Journal of Medicinal Chemistry · 2021 · 30 citations · Full text